Observational studyClinical rheumatology2025
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Observational study in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Complex-to-manage and treatment-refractory psoriatic arthritis in Argentina: real-world evidence from the RECCAPSO network.Clinical rheumatology · 2026Article
- Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database.Clinical rheumatology · 2026Observational
- Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.Arthritis research & therapy · 2026Article
- Patients with poorer health status are more likely to have difficult-to-manage axial spondyloarthritis: insights from a real-world cohort.Therapeutic advances in musculoskeletal disease · 2026Article
- Prevalence and clinical factors associated with difficult-to-manage axial spondyloarthritis: a multicentre Italian cohort study with meta-analysis.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA), recently defined by ASAS, identifies patients with persistent active disease despite failure of ≥ 2 b/tsDMARDs with different mechanisms of action. Refractory axSpA (TR) represents a more severe subset with objective signs of inflammation.
objectiveTo estimate the frequency of D2M in the Reuma-Check axSpA cohort, describe treatment trajectories, and identify baseline characteristics associated with D2M.
methodsThis prospective observational study (2017-2024) included axSpA patients ≥ 18 years old assessed via the structured Reuma-Check protocol. Baseline data included demographics, sacroiliac imaging (X-ray, MRI), ultrasound, CRP, and disease activity measures (BASDAI, ASDAS, BASFI). D2M was defined using ASAS criteria. Comparative and logistic regression analyses were performed to identify associated factors.
resultsAmong 129 axSpA patients, 11 (8.53%) met criteria for D2M. Only four fulfilled criteria for TR. Compared to non-D2M, these patients showed significantly higher BASFI (4.2 vs. 2.9), BASDAI (5.1 vs. 3.5), and ASDAS (3.7 vs. 2.8). Significant categorical predictors included smoking, psoriasis, sacroiliac joint tenderness, and peripheral structural damage. Articular ultrasound abnormalities were present in 75% of D2M patients and emerged as the only independent predictor (OR = 10.65; 95% CI: 1.42-80.09). Regarding treatment patterns, 50% of patients initiated b/tsDMARDs; 30% failed first-line therapy, and 57% of those failed second-line treatment. Third-line therapies included JAK inhibitors (54%), IL-17 inhibitors (27%), and TNFi (19%).
conclusionD2M-axSpA was identified in approximately 9% of patients using ASAS criteria. A combination of clinical and imaging features-especially ultrasound-may assist in early identification and tailored management. Key Points • D2M-axSpA affects nearly 9% of patients in real-world clinical practice. • Clinical and structural predictors such as psoriasis and joint damage are associated with D2M. • Articular ultrasound is a key tool for identifying high-risk patients.
Indexed as
Identifiers
40782277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.